[{"address1": "2450 Holcombe Boulevard", "address2": "Suite X", "city": "Houston", "state": "TX", "zip": "77021", "country": "United States", "phone": "832 834 9144", "website": "https://www.salariuspharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.", "fullTimeEmployees": 2, "companyOfficers": [{"maxAge": 1, "name": "Mr. David J. Arthur M.B.A.", "age": 60, "title": "CEO, President & Director", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 343200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark J. Rosenblum CPA", "age": 70, "title": "Executive VP of Finance & CFO", "yearBorn": 1953, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.47, "open": 1.46, "dayLow": 1.44, "dayHigh": 1.5, "regularMarketPreviousClose": 1.47, "regularMarketOpen": 1.46, "regularMarketDayLow": 1.44, "regularMarketDayHigh": 1.5, "beta": 0.932, "forwardPE": -0.16357689, "volume": 25684, "regularMarketVolume": 25684, "averageVolume": 356778, "averageVolume10days": 55930, "averageDailyVolume10Day": 55930, "bid": 1.45, "ask": 1.52, "bidSize": 100, "askSize": 100, "marketCap": 2161740, "fiftyTwoWeekLow": 1.26, "fiftyTwoWeekHigh": 7.272, "fiftyDayAverage": 1.5769, "twoHundredDayAverage": 3.06285, "currency": "USD", "enterpriseValue": -1111087, "floatShares": 1404883, "sharesOutstanding": 1441160, "sharesShort": 1528, "sharesShortPriorMonth": 9397, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0011, "heldPercentInsiders": 0.02517, "heldPercentInstitutions": 0.01812, "shortPercentOfFloat": 0.0011, "bookValue": 3.705, "priceToBook": 0.40485832, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -6464335, "trailingEps": -8.73, "forwardEps": -9.17, "lastSplitFactor": "1:25", "lastSplitDate": 1563753600, "enterpriseToEbitda": 0.165, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SLRX", "underlyingSymbol": "SLRX", "shortName": "Salarius Pharmaceuticals, Inc.", "longName": "Salarius Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1422541800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "f7c5d494-3e4a-33bc-9704-e2b0ec3dd19f", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.5, "targetHighPrice": 26.0, "targetLowPrice": 26.0, "targetMeanPrice": 26.0, "targetMedianPrice": 26.0, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 1, "totalCash": 3272823, "totalCashPerShare": 2.271, "ebitda": -6733092, "quickRatio": 2.777, "currentRatio": 2.982, "returnOnAssets": -0.53991, "returnOnEquity": -1.1983, "freeCashflow": -6133413, "operatingCashflow": -7686402, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-11"}]